Three years after the original Apple Watch launched with a heart rate monitor, Apple dramatically improved the cardiovascular functionality by adding electrocardiogram recording to the Apple Watch Series 4.Now the company will partner with Johnson & Johnson’s Janssen Pharmaceuticals unit to study whether the wearable can also be used to prevent strokes.The study appears to be focusing on the latest Apple Watch’s ability to detect atrial fibrillation (AFib) earlier than prior models, which might enable the Series 4 model to suss out a leading cause of strokes.Apple added occasional background checks for AFib to Series 1 through 3 models last December, relying on the results of five heart rhythm readings, but the new Apple Watch might be able to provide better and faster warning.Johnson & Johnson chief scientific officer Paul Stoffels explained that “the goal is to identify early on AFib and prevent stroke by combining the physical know-how from Apple and what we have from the medical and scientific know-how.”“We are receiving thank you letters daily from Apple Watch wearers who are discovering they have AFib,” said Apple COO Jeff Williams.
The world's largest healthcare company said results from a small, early study of its coronavirus vaccine were promising.
The company said last week the single-dose vaccine was 66% effective in preventing COVID-19.
Johnson & Johnson has applied for a COVID-19 Emergency Use Authorization (EUA) from the FDA, the company announced on Thursday, February 4. The application pertains to J&J’s Janssen COVID-19 vaccine candidate, a single-shot product that is ready to be shipped to distributors ‘immediately following authorization,’ Johnson & Johnson said. On January 29, Johnson & Johnson announced that its single-shot COVID-19 … Continue reading
The Johnson & Johnson single-shot COVID-19 vaccine can in very rare cases lead to unusual blood clots, the European Medicines Agency has concluded, though experts maintain the benefits outweigh the risks. It’s the second coronavirus vaccine to be subject to extra warning labeling by the EU regulator, after AstraZeneca’s drug was also linked to blood clotting issues. Then, as now, … Continue reading
Johnson & Johnson shares climbed Tuesday as the drug maker restarts shipments of its coronavirus vaccine to the European Union.
Rare but potentially fatal blood clots have surfaced in 15 women who got Johnson & Johnson's vaccine. But COVID-19 is a much greater threat.
The COVID-19 shot will now come with a warning about rare blood clots occurring in women under 50.